This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.
Read more
ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
ITM Obtains Manufacturing License in the U.S.
ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics
ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023
ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
Phone: +49 89 329 8986 1500
E-Mail: communications(at)itm-radiopharma.com
Press Archive